Diagnostic and prognostic needs in neurodegenerative disorders: focus on proteomics

References

• Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer’s disease. Brain129, 2840–2855 (2006).
   PubMed Web of Science ®Google Scholar
• Braak H, Braak E. Diagnostic criteria for neuropathologic assessment of Alzheimer’s disease. Neurobiol. Aging18, 85–88 (1997).
   PubMed Web of Science ®Google Scholar
• Glenner GG, Wong CW. Alzheimer’s disease and Down’s syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun.122, 1131–1135 (1984).
   PubMed Web of Science ®Google Scholar
• Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc. Natl Acad. Sci. USA83, 4044–4048 (1986).
   PubMed Web of Science ®Google Scholar
• Vandermeeren M, Mercken M, Vanmechelen E et al. Detection of proteins in normal an Alzheimer’s disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J. Neurochem.61, 1828–1834 (1993).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Ågren H et al. Tau protein in cerebrospinal fluid: a biochemical diagnostic marker for axonal degeneration in Alzheimer’s disease? Mol. Chem. Neuropathol.26, 231–245 (1995).
   PubMedGoogle Scholar
• Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of β-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol.38, 643–648 (1995).
   PubMed Web of Science ®Google Scholar
• The Working Group on: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’, Consensus report of the Working Group on: ‘Molecular and Biochemical Markers of Alzheimer’s Disease’. The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association and the National Institute on Aging Working Group. Neurobiol. Aging19, 109–116 (1998).
   PubMed Web of Science ®Google Scholar
• Dubios B, Feldman HW, Jacova C et al. Research criteria for the diagnosis of Alzheimer’s disease: revising the NINCDS–ADRDA criteria. Lancet Neurol.6, 734–746 (2007).
   PubMedGoogle Scholar
• Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer’s disease. NeuroRx1, 213–225 (2004).
   PubMedGoogle Scholar
• Shoji M, Matsubara E, Kanai M et al. Combination assay of CSF tau, Aβ1–40 and Aβ1–42(43) as a biochemical marker of Alzheimer’s disease. J. Neurol. Sci.158, 134–140 (1998).
   PubMed Web of Science ®Google Scholar
• Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD-patients using β-amyloid (1–42) and tau levels in CSF. Neurology52, 1555–1562 (1999).
   PubMed Web of Science ®Google Scholar
• Maddalena A, Papassotiropoulos A, Mueller-Tillmanns B et al. Cerebrospinal fluid amyloid β42/phosphorylated tau ratio discriminates between Alzheimer’s disease and vascular dementia. Arch. Neurol.60, 1202–1206 (2003).
   PubMedGoogle Scholar
• Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Ab42, Ab42/Ab40 ratio and total tau. Neurobiol. Aging25, 273–281 (2004).
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J. Neurochem.81, 481–496 (2002).
   PubMed Web of Science ®Google Scholar
• Bibl M, Mollenhauer B, Esselmann H et al. CSF amyloid-β-peptides in Alzheimer’s disease, dementia with Lewy bodies and Parkinson’s disease dementia. Brain129, 1177–1187 (2006).
   PubMed Web of Science ®Google Scholar
• Bibl M, Mollenhauer B, Esselmann H et al. CSF diagnosis of Alzheimer’s disease and dementias with Lewy bodies. J. Neural Transm.113, 1771–1778 (2006).
   PubMedGoogle Scholar
• Bibl M, Mollenhauer B, Wolf S et al. Reduced CSF carboxyterminally truncated Aβ petides in frontotemporal lobe degenerations. J. Neural Transm.114, 621–628 (2007).
   PubMedGoogle Scholar
• Bibl M, Mollenhauer B, Lewczuk et al. Validation of amyloid-β peptides in CSF diagnosis of neurodegenerative dementias. Mol. Psychiatry12, 671–680 (2007).
   PubMed Web of Science ®Google Scholar
• Hansson O, Zetterberg H, Buchhave P et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol.5, 228–234 (2006).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Kornhuber J, Vanderstichele H et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol. Aging PMID: 17239996 (2006) (Epub ahead of print).
   Google Scholar
• Wiltfang J, Esselmann H, Bibl M et al. Amyloid β peptide ratio 42/40 but not Aβ42 correlates with phospho-Tau in patients with low- and high-CSF A β 40 load. J. Neurochem.101, 1053–1059 (2007).
   PubMed Web of Science ®Google Scholar
• van Oijen M, Hofman A, Soares HD et al. Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case–cohort study. Lancet Neurol.5, 655–660 (2006).
   PubMed Web of Science ®Google Scholar
• Bibl M, Esselmann H, Mollenhauer B et al. Blood-based neurochemical diagnosis of vascular dementia: a pilot study. J. Neurochem.103, 467–474 (2007).
   PubMed Web of Science ®Google Scholar
• Ray S, Britschgi M, Herbert C et al. Classification and prediction of clinical Alzheimer’s diagnosis based on plasma signaling proteins. Nat. Med.13(11), 1359–1362 (2007).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Kornhuber J, Wiltfang J. The German Competence Net Dementias: standard operating procedures for the neurochemical dementia diagnostics. J. Neural Transm.113, 1075–1080 (2006).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett.409, 1–4 (2006).
   PubMedGoogle Scholar